EM703, the new derivative of erythromycin, inhibits transcription of type I collagen in normal and scleroderma fibroblasts

Journal of Dermatological Science

Volumn 49, Issue 3, 2008, Pages 195-205

  Ikeda, Hideyuki ^a   Sunazuka, Toshiaki ^b   Suzuki, Hiromi ^a   Hamasaki, Yoichiro ^a   Yamazaki, Soji ^a   Omura, Satoshi ^b   Hatamochi, Atsushi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Collagen gene expression; Derivative of erythromycin; EM703; Fibroblasts; Systemic sclerosis; Transcription

Indexed keywords

BLEOMYCIN; CCAAT ENHANCER BINDING PROTEIN; COLLAGEN ANTIBODY; COLLAGEN TYPE 1; ERYTHROMYCIN; LUCIFERASE; MESSENGER RNA;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SCLERODERMA; SUBSTITUTION REACTION;

ADULT; ANTI-BACTERIAL AGENTS; CCAAT-BINDING FACTOR; CELL PROLIFERATION; COLLAGEN TYPE I; ERYTHROMYCIN; FEMALE; FIBROBLASTS; HUMANS; INFANT; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SCLERODERMA, SYSTEMIC; TRANSCRIPTION, GENETIC;

EID: 38749089806     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2007.10.006     Document Type: Article

References (44)

1. Jimenez S.A., Hitraya E., and Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 22 (1996) 647-674
2. Saitta B., Gaidarova S., Cicchillitti L., and Jimenez S.A. CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts. Arthritis Rheum 43 (2000) 2219-2229
3. Black C.M., Silman A.J., Herrick A.I., Denton C.P., Wilson H., Newman J., et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42 (1999) 299-305
4. Clements P.J., Furst D.E., Wong W.K., Mayes M., White B., Wigley F., et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42 (1999) 1194-1203
5. Polisson R.P., Gilkeson G.S., Pyun E.H., Pisetsky D.S., Smith E.A., Simon L.S., et al. A multicenter trial of recombinant human interferon γ in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 23 (1996) 654-658
6. Seibold J.R., Korn J.H., Simms R., Clements P.J., Moreland L.W., Mayes M.D., et al. Recombinant human relaxin in the treatment of scleroderma: a randomized, double, placebo-controlled trial. Ann Intern Med 132 (2000) 871-879
7. Denton C.P., Merkel A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis: a muiticenter, randomized, placebocontrolled phase I/II trial of CAT-192. Arthritis Rheum 56 (2007) 323-333
8. Ianaro A., Ialenti A., Maffia P., Sautebin L., Rombola L., Carnuccio R., et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292 (2000) 156-163
9. Yatsunami J., Fukuno Y., Nagata M., Tominaga M., Aoki S., Tsuruta N., et al. Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin Exp Metastas 17 (1999) 361-367
10. Nonaka M., Pawankar R., Tomiyama S., and Yagi T. A macrolide antibiotic roxithromycin inhibits the growth of nasal polyp fibroblasts. Am J Rhinol 13 (1999) 267-272
11. Gaylor A.S., and Reilly J.C. Therapy with macrolides in patients with cystic fibrosis. Pharmacotherapy 22 (2002) 227-239
12. Southern K.W., and Barker P.M. Azithromycin for cystic fibrosis. Eur Respir J 24 (2004) 834-838
13. Li J.Y., Azuma A., Usuki J., Abe S., Matsuda K., Sunazuka T., et al. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts. Respir Res 7 (2006) 1-13
14. Desaki M., Okazaki H., Sunazuka T., Omura S., Yamamoto K., and Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappa B activation. Antimicrob Agents Chemother 48 (2004) 1581-1585
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. Yoshida K., Sunazuka T., Nagai K., Sugawara A., Cho A., Nagamitsu T., et al. Macrolides with promotive activity of monocyte to macrophage differentiation. J Antibiot 58 (2005) 79-81
17. Fleischmajer R., Perlish J.S., Krieg T., and Timple R. Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol 76 (1981) 400-403
18. Hatamochi A., Arakawa M., Takeda K., and Ueki H. Activation of fibroblast proliferation by Werner's syndrome fibroblast-conditioned medium. J Dermatol Sci 7 (1994) 210-216
19. Chu M.L., Myers J.C., Bernard M.P., Ding J.F., and Ramirez F. Cloning and characterization of five overlapping cDNAs specific for the human pro alpha 1(I) collagen chain. Nucleic Acids Res 10 (1982) 5925-5934
20. de Wet W., Bernard M., Benson-Chanda V., Chu M.L., Dickson L., Weil D., et al. Organization of the human pro-α2(I) collagen gene. J Biol Chem 262 (1987) 16032-16036
21. Arcari P., Martinelli R., and Salvatore F. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res 12 (1984) 9179-9189
22. Mori K., Hatamochi A., Ueki H., Olsen A., and Jimenez S.A. The transcription of human α1(I) procollagen gene (COL1A1) is suppressed by tumor necrosis factor-α through proximal short promoter elements-evidence for suppression mechanisms mediated by two nuclear factor binding sites. Biochem J 319 (1996) 811-816
23. Henikoff S. Unidirectional digestion with exonuclease III creates targeted breakpoints for DNA sequencing. Gene 28 (1984) 351-359
24. Sato M., Shegogue D., Hatamochi A., Yamazaki S., and Trojanowska M. Lysophosphatidic acid inhibits TGF-beta-mediated stimulation of type I collagen mRNA stability via an ERK-dependent pathway in dermal fibroblasts. Matrix Biol 23 (2004) 353-361
25. Groudine M., Peretz M., and Weintraub H. Transcriptional regulation of hemoglobin switching in chicken embryos. Mol Cell Biol 1 (1981) 281-288
26. Hatamochi A., Mori K., Arakawa M., Ueki H., and Kondo M. Collagenase gene expression in cutis laxa fibroblasts is upregulated by transcriptional activation of the promoter gene through a 12-O-tetradecanoyl-phorbol-13-acerate (TPA)-responsive element. J Invest Dermatol 106 (1996) 631-636
27. Louneva N., Saitta B., Herrick D.J., and Jimenez S.A. Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. J Biol Chem 278 (2003) 40400-40407
28. Jimenez S.A., Varga J., Olsen A., Li L., Diaz A., Herhal J., et al. Functional analysis of human α1(I) procollagen gene promoter-differential activity in collagen-producing and nonproducing cells and response to transforming growth factor β1. J Biol Chem 269 (1994) 12684-12691
29. Geesin J.C., Darr D., Kaufman R., Murad S., and Pinnell S.R. Ascorbic acid specifically increases type I and type III procollagen messenger RNA levels in human skin fibroblast. J Invest Dermatol 90 (1988) 420-424
30. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83 (1986) 4167-4171
31. Verrecchia F., and Mauviel A. Control of connective tissue gene expression by TGF-β: role of Smad proteins in fibrosis. Curr Rheumatol Rep 4 (2002) 143-149
32. Duncan M.R., and Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 97 (1991) 686-692
33. Falanga V., Martin T.A., Takagi H., Kirsner R.S., Helfman T., Pardes J., et al. Low oxygen tension increases mRNA levels of alpha 1(I) procollagen in human dermal fibroblasts. J Cell Physiol 157 (1993) 408-412
34. Greenwel P., Tanaka S., Penkov D., Zhang W., Olive M., Moll J., et al. Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. Mol Cell Biol 20 (2000) 912-918
35. Ghosh A.K., Yuan W., Mori Y., Chen S.-J., and Varga J. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276 (2001) 11041-11048
36. Kurata S., and Hata R. Epidermal growth factor inhibits transcription of type I collagen genes and production of type I collagen in cultured human skin fibroblasts in the presence and absence of l-ascorbic acid 2-phosphate, a long-acting vitamin C derivative. J Biol Chem 266 (1991) 9997-10003
37. Hamalainen L., Oikarinen J., and Kivirikko K.I. Synthesis and degradation of type I procollagen mRNAs in cultured human skin fibroblasts and the effect of cortisol. J Biol Chem 260 (1985) 720-725
38. Sandmeyer S., Gallis B., and Bornstein P. Coordinate transcriptional regulation of type I procollagen genes by Rous sarcoma virus. J Biol Chem 256 (1981) 5022-5028
39. Hatamochi A., Aumailley M., Mauch C., Chu M.L., Timpl R., and Krieg T. Regulation of collagen VI expression in fibroblasts. Effects of cell density, cell-matrix interactions, and chemical transformation. J Biol Chem 264 (1989) 3494-3499
40. Yatsunami J., Tsuruta N., Hara N., and Hayashi S. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 131 (1998) 137-143
41. Aoki D., Ueno S., Kubo F., Oyama T., Sakuta T., Matsushita K., et al. Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. Anticancer Res 25 (2005) 133-138
42. Kobayashi M., Shimauchi T., Hino R., and Tokura Y. Roxithromycin down modulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors. Cell Immunol 228 (2004) 27-33
43. Maity S.N., Golumbek P.T., Karsenty G., and de Crombrugghe B. Selective activation of transcription by a novel CCAAT binding factor. Science 241 (1988) 582-585
44. Ravazzolo R., Karsenty G., and de Crombrugghe B. A fibroblast-specific factor binds to an upstream negative control element in the promoter of the mouse alpha 1(I) collagen gene. J Biol Chem 266 (1991) 7382-7387